Interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-alpha) serum level at baseline (T0), during antiviral treatment (T4wk and EoT), and after the end of therapy (SVR4 and SVR12).

<p>(A) IL-10 concentration decreased after 4 weeks of treatment (p = 0.03 vs. T0) and at EoT (p = 0.01 vs. T0); the level of IL-10 remained low up to SVR12. (B) TNF-alpha decreased progressively during treatment and reached statistical significance at the end of treatment (p = 0.05 vs. T0). The median significantly decreased after the end of treatment, at SVR4 and SVR12 (p<0.01). IL-10 and TNF-alpha are shown as the median and interquartile range (IQR). Outliers are not reported. *: p≤0.05 and **: p<0.01 vs. baseline. T0: baseline; T4wk: after 4 weeks of therapy; EoT: end of treatment; SVR4: 4 weeks after the end of treatment; SVR12: 12 weeks after the end of treatment.